ORION: Durvalumab plus Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Ahn, M. [1 ]
Liu, Y. [2 ]
Improta, T. [3 ]
Marcovitz, M. [2 ]
Dipiazza, K. [2 ]
Lanasa, M. [2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Astrazeneca, Gaithersburg, MD USA
[3] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2019.08.1362
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-18
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
    Altorki, Nasser K.
    Walsh, Zachary H.
    Melms, Johannes C.
    Port, Jeffery L.
    Lee, Benjamin E.
    Nasar, Abu
    Spinelli, Cathy
    Caprio, Lindsay
    Rogava, Meri
    Ho, Patricia
    Christos, Paul J.
    Saxena, Ashish
    Elemento, Olivier
    Bhinder, Bhavneet
    Ager, Casey
    Amin, Amit Dipak
    Sanfilippo, Nicholas J.
    Mittal, Vivek
    Borczuk, Alain C.
    Formenti, Sylvia C.
    Izar, Benjamin
    Mcgraw, Timothy E.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [22] Nivolumab Plus Ipilimumab in Relapsed Stage III Non-Small Cell Lung Cancer After Durvalumab Following Chemoradiotherapy
    Tokito, T.
    Mouri, A.
    Watanabe, S.
    Nagai, Y.
    Imai, H.
    Yamaguchi, O.
    Saida, Y.
    Kobayashi, K.
    Kaira, K.
    Kagamu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S589 - S589
  • [23] Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results
    Huang, Yan
    Jia, Jun
    Wang, Qiming
    Liu, Xianling
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)
    Raben, D.
    Rimner, A.
    Senan, S.
    Broadhurst, H.
    Pellas, T.
    Dennis, P. A.
    Faivre-Finn, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 683 - 683
  • [25] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [26] Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
    De Ruysscher, Dirk
    Remon, Jordi
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 149 - 151
  • [27] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [28] Real world experience of survival outcomes in consolidative durvalumab in unresectable stage III non-small cell lung cancer (NSCLC)
    Pringle, Nicole
    Fletcher, James
    Arneil, Melissa
    Xu, Wen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 47 - 48
  • [29] Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
    Chiramel, Jaseela
    Tay, Rebecca
    Califano, Raffaele
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S991 - S994
  • [30] Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Pringle, N.
    Fletcher, J. A.
    Morton, C.
    Mullally, W. J.
    Arneil, M.
    O'Byrne, K.
    Xu, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S569 - S569
12345